COMPASS Pathways Contracts with Worldwide Clinical Trials as its CRO for its First Large-scale Controlled Trials

COMPASS Pathways has contracted with Worldwide Clinical Trials as its CRO for its first ever large-scale randomized, controlled trials, covering 400 patients with treatment-resistant depression in eight countries. The trial will begin in the first quarter of 2018 and is planned to include clinical sites in Czech Republic, Finland, Germany, the Netherlands, Norway, Portugal, Spain and the UK.

Read the full release here.